$TTNP
TITAN PHARMACEUTICALS INC

2021 Q4 Form 10-K Financial Statement

#000141057822000518 Filed on March 25, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 2020 Q4
Revenue $135.0K $1.526M $1.270M
YoY Change -89.37% -68.46% 504.76%
Cost Of Revenue $0.00 $199.0K -$440.0K
YoY Change -100.0% -57.84% -40.54%
Gross Profit $135.0K $1.327M $1.710M
YoY Change -92.11% -69.61% 80.0%
Gross Profit Margin 100.0% 86.96% 134.65%
Selling, General & Admin $1.648M $4.989M -$2.510M
YoY Change -165.66% -13.98% -36.29%
% of Gross Profit 1220.74% 375.96% -146.78%
Research & Development $976.0K $5.692M $540.0K
YoY Change 80.74% -3.79% -286.21%
% of Gross Profit 722.96% 428.94% 31.58%
Depreciation & Amortization $53.00K $221.0K $60.00K
YoY Change -11.67% -24.32% 20.0%
% of Gross Profit 39.26% 16.65% 3.51%
Operating Expenses $2.624M $5.692M -$1.890M
YoY Change -238.84% -3.79% -55.21%
Operating Profit -$2.489M -$9.354M $3.600M
YoY Change -169.14% 27.25% -30.37%
Interest Expense $3.000K $1.000K $1.920M
YoY Change -99.84% -100.13% -1300.0%
% of Operating Profit 53.33%
Other Income/Expense, Net -$54.00K $578.0K -$30.00K
YoY Change 80.0% -1132.14% -400.0%
Pretax Income -$2.540M -$8.776M $5.500M
YoY Change -146.18% 18.43% 9.34%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$2.540M -$8.776M -$3.090M
YoY Change -17.8% -51.89% -21.57%
Net Earnings / Revenue -1881.48% -575.1% -243.31%
Basic Earnings Per Share
Diluted Earnings Per Share -$256.7K -$902.0K -$515.9K
COMMON SHARES
Basic Shares Outstanding 9.914M 9.730M
Diluted Shares Outstanding 9.730M

Balance Sheet

Concept 2021 Q4 2021 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.037M $6.037M $5.400M
YoY Change 11.8% 11.8% 3.85%
Cash & Equivalents $6.037M $5.413M
Short-Term Investments
Other Short-Term Assets $787.0K $787.0K $700.0K
YoY Change 12.43% 12.43% -36.36%
Inventory $293.0K $293.0K $328.0K
Prepaid Expenses
Receivables $112.0K $112.0K $884.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $7.229M $7.229M $7.328M
YoY Change -1.35% -0.97% -11.71%
LONG-TERM ASSETS
Property, Plant & Equipment $420.0K $717.0K $618.0K
YoY Change -32.04% -10.38% -48.5%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $48.00K $48.00K $0.00
YoY Change
Total Long-Term Assets $765.0K $765.0K $759.0K
YoY Change 0.79% -4.38% -36.75%
TOTAL ASSETS
Total Short-Term Assets $7.229M $7.229M $7.328M
Total Long-Term Assets $765.0K $765.0K $759.0K
Total Assets $7.994M $7.994M $8.087M
YoY Change -1.15% -1.31% -14.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $795.0K $795.0K $1.253M
YoY Change -36.55% -38.85% -10.5%
Accrued Expenses $435.0K $435.0K $700.0K
YoY Change -37.86% -37.86% -50.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00 $327.0K
YoY Change -100.0% -100.0%
Total Short-Term Liabilities $2.669M $2.669M $4.223M
YoY Change -36.8% -36.45% 17.31%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $332.0K
YoY Change -100.0% -100.0% -91.7%
Other Long-Term Liabilities $187.0K $187.0K $0.00
YoY Change -100.0%
Total Long-Term Liabilities $0.00 $187.0K $332.0K
YoY Change -100.0% -37.67% -92.62%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.669M $2.669M $4.223M
Total Long-Term Liabilities $0.00 $187.0K $332.0K
Total Liabilities $2.856M $2.856M $4.555M
YoY Change -37.3% -37.91% -43.77%
SHAREHOLDERS EQUITY
Retained Earnings -$376.1M -$367.3M
YoY Change 2.39%
Common Stock $10.00K $7.000K
YoY Change 42.86%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $5.138M $5.138M $3.532M
YoY Change
Total Liabilities & Shareholders Equity $7.994M $7.994M $8.087M
YoY Change -1.15% -1.31% -14.87%

Cashflow Statement

Concept 2021 Q4 2021 2020 Q4
OPERATING ACTIVITIES
Net Income -$2.540M -$8.776M -$3.090M
YoY Change -17.8% -51.89% -21.57%
Depreciation, Depletion And Amortization $53.00K $221.0K $60.00K
YoY Change -11.67% -24.32% 20.0%
Cash From Operating Activities -$1.081M -$7.899M -$4.560M
YoY Change -76.29% -54.08% 24.25%
INVESTING ACTIVITIES
Capital Expenditures -$5.000K $23.00K -$10.00K
YoY Change -50.0% -95.74% -91.67%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$5.000K -$23.00K -$10.00K
YoY Change -50.0% -95.74% -91.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net $0.00
YoY Change -100.0%
Cash From Financing Activities 0.000 8.841M 5.910M
YoY Change -100.0% -50.7% -26.86%
NET CHANGE
Cash From Operating Activities -1.081M -7.899M -4.560M
Cash From Investing Activities -5.000K -23.00K -10.00K
Cash From Financing Activities 0.000 8.841M 5.910M
Net Change In Cash -1.086M 919.0K 1.340M
YoY Change -181.04% 383.68% -68.76%
FREE CASH FLOW
Cash From Operating Activities -$1.081M -$7.899M -$4.560M
Capital Expenditures -$5.000K $23.00K -$10.00K
Free Cash Flow -$1.076M -$7.922M -$4.550M
YoY Change -76.35% -55.35% 28.17%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9730000
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3773000
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0000910267
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9914158
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9914158
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7139068
CY2021 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.90
CY2020Q4 us-gaap Restricted Cash
RestrictedCash
0
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
112000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
884000
CY2021Q4 us-gaap Inventory Net
InventoryNet
293000
CY2020Q4 us-gaap Inventory Net
InventoryNet
328000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
480000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
522000
CY2020 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-1.96
CY2021 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.00
CY2020 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-2.87
CY2020Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.0333
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-13341
CY2021 dei Entity Registrant Name
EntityRegistrantName
TITAN PHARMACEUTICALS, INC.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
94-3171940
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
400 Oyster Point Blvd., 
CY2021 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 505,
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
CY2021 dei City Area Code
CityAreaCode
650
CY2021 dei Local Phone Number
LocalPhoneNumber
244-4990
CY2021 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001
CY2021 dei Trading Symbol
TradingSymbol
TTNP
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
25600000
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12039421
CY2021 dei Auditor Name
AuditorName
WithumSmith+Brown, PC
CY2021 dei Auditor Location
AuditorLocation
San Francisco, California
CY2021 dei Auditor Firm
AuditorFirmId
100
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6037000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5413000
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
295000
CY2021Q4 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
12000
CY2020Q4 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
181000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
7229000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
7328000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
420000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
618000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
48000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
0
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
297000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
141000
CY2021Q4 us-gaap Assets
Assets
7994000
CY2020Q4 us-gaap Assets
Assets
8087000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
795000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1253000
CY2021Q4 ttnp Accrued Clinical Trials Expenses Current
AccruedClinicalTrialsExpensesCurrent
9000
CY2020Q4 ttnp Accrued Clinical Trials Expenses Current
AccruedClinicalTrialsExpensesCurrent
214000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
314000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
319000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
112000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
150000
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
0
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
327000
CY2021Q4 ttnp Deferred Grant Revenue
DeferredGrantRevenue
295000
CY2020Q4 ttnp Deferred Grant Revenue
DeferredGrantRevenue
0
CY2021Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
1144000
CY2020Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
1960000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2669000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4223000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
332000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
187000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2021Q4 us-gaap Liabilities
Liabilities
2856000
CY2020Q4 us-gaap Liabilities
Liabilities
4555000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
225000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
225000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9914158
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7139068
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
10000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
7000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
381183000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
370804000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-376055000
CY2020 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
472000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5692000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5916000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4989000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5801000
CY2021 us-gaap Costs And Expenses
CostsAndExpenses
10880000
CY2020 us-gaap Costs And Expenses
CostsAndExpenses
12189000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-9354000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-7351000
CY2021 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1000
CY2020 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-769000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-84000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-258000
CY2021 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-367279000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
5138000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
3532000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7994000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8087000
CY2021 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1526000
CY2020 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
4838000
CY2021 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
199000
CY2020 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
923000
CY2021 ttnp Gain Loss On Difference Between Fair And Carrying Value Of Assets
GainLossOnDifferenceBetweenFairAndCarryingValueOfAssets
0
CY2020 ttnp Gain Loss On Difference Between Fair And Carrying Value Of Assets
GainLossOnDifferenceBetweenFairAndCarryingValueOfAssets
1975000
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
661000
CY2020 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-81000
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
578000
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-56000
CY2021 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-8776000
CY2020 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-7407000
CY2021 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
0
CY2020 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-10835000
CY2021 ttnp Net Income Loss And Comprehensive Income Loss
NetIncomeLossAndComprehensiveIncomeLoss
-8776000
CY2020 ttnp Net Income Loss And Comprehensive Income Loss
NetIncomeLossAndComprehensiveIncomeLoss
-18242000
CY2021 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.90
CY2020 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-1.96
CY2021 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0
CY2020 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-2.87
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9730000
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3773000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
1433000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-18242000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
10194000
CY2020 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
7243000
CY2020 ttnp Stock Issued During Period Values Reverse Stock Splits
StockIssuedDuringPeriodValuesReverseStockSplits
0
CY2020 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
2897000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
3532000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-8776000
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
8841000
CY2021 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
36000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1505000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
5138000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-8776000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-18242000
CY2021 ttnp Gain Loss On Difference Between Fair And Carrying Value Of Assets
GainLossOnDifferenceBetweenFairAndCarryingValueOfAssets
0
CY2020 ttnp Gain Loss On Difference Between Fair And Carrying Value Of Assets
GainLossOnDifferenceBetweenFairAndCarryingValueOfAssets
1975000
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
221000
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
292000
CY2021 us-gaap Other Noncash Expense
OtherNoncashExpense
2000
CY2020 us-gaap Other Noncash Expense
OtherNoncashExpense
498000
CY2021 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
CY2020 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
923000
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
661000
CY2020 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-81000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
1541000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
7000
CY2021 us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
0
CY2020 us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
211000
CY2021 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
7000
CY2020 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
16000
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-772000
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-186000
CY2021 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-35000
CY2020 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-287000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-163000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-391000
CY2021 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1191000
CY2020 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1101000
CY2021 ttnp Increase Decrease In Accrued Sales Allowances
IncreaseDecreaseInAccruedSalesAllowances
0
CY2020 ttnp Increase Decrease In Accrued Sales Allowances
IncreaseDecreaseInAccruedSalesAllowances
-747000
CY2021 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-293000
CY2020 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-200000
CY2021 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
295000
CY2020 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
0
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7899000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17203000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
23000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
540000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-23000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-540000
CY2021 ttnp Proceeds From Equity Offerings
ProceedsFromEquityOfferings
8841000
CY2020 ttnp Proceeds From Equity Offerings
ProceedsFromEquityOfferings
11636000
CY2021 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0
CY2020 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
654000
CY2021 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
CY2020 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
7243000
CY2020Q4 ttnp Cash And Cash Equivalents And Restricted Cash Equivalents
CashAndCashEquivalentsAndRestrictedCashEquivalents
5413000
CY2021 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0
CY2020 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1600000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8841000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
17933000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
919000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
190000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5413000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5223000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6332000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5413000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
0
CY2020 us-gaap Interest Paid Net
InterestPaidNet
295000
CY2021 ttnp Right Of Use Asset Obtained In Exchange For Lease Liability Net Of Amortization
RightOfUseAssetObtainedInExchangeForLeaseLiabilityNetOfAmortization
149000
CY2020 ttnp Right Of Use Asset Obtained In Exchange For Lease Liability Net Of Amortization
RightOfUseAssetObtainedInExchangeForLeaseLiabilityNetOfAmortization
-272000
CY2021 us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
1372000
CY2020 us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
0
CY2021 us-gaap Accumulated Depreciation Depletion And Amortization Sale Of Property Plant And Equipment1
AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1
1372000
CY2020 us-gaap Accumulated Depreciation Depletion And Amortization Sale Of Property Plant And Equipment1
AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1
0
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6037000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5413000
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
295000
CY2021Q4 ttnp Cash And Cash Equivalents And Restricted Cash Equivalents
CashAndCashEquivalentsAndRestrictedCashEquivalents
6332000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6000000.0
CY2021 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
5000000.0
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</p>
CY2021Q4 us-gaap Inventory Raw Materials And Supplies Net Of Reserves
InventoryRawMaterialsAndSuppliesNetOfReserves
227000
CY2020Q4 us-gaap Inventory Raw Materials And Supplies Net Of Reserves
InventoryRawMaterialsAndSuppliesNetOfReserves
170000
CY2021Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
66000
CY2020Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
158000
CY2021Q4 us-gaap Inventory Net
InventoryNet
293000
CY2020Q4 us-gaap Inventory Net
InventoryNet
328000
CY2021Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
66000
CY2020Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
158000
CY2021Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
5700000
CY2020Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
5100000
CY2020Q4 us-gaap Contract With Customer Asset Gross
ContractWithCustomerAssetGross
884000
CY2021 ttnp Contract With Customer Asset Additions
ContractWithCustomerAssetAdditions
1526000
CY2021 ttnp Contract With Customer Asset Deductions
ContractWithCustomerAssetDeductions
2298000
CY2021Q4 us-gaap Contract With Customer Asset Gross
ContractWithCustomerAssetGross
112000
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3008000
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
328000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
127000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
130000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
66000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
323000
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
24000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
299000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1817000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3166000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1397000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2548000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
420000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
618000
CY2020Q4 us-gaap Debt And Capital Lease Obligations
DebtAndCapitalLeaseObligations
1600000
CY2021 ttnp Operating Leases Rent Expenses
OperatingLeasesRentExpenses
200000
CY2020 ttnp Operating Leases Rent Expenses
OperatingLeasesRentExpenses
300000
CY2021Q4 ttnp Minimum Manufacturing Fee Payable
MinimumManufacturingFeePayable
1000000.0
CY2019Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
320000
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
1654000
CY2020 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
923000
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
-2897000
CY2020Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
0
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9914158
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7139068
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
50000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
0
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
50000
CY2020 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
7200000
CY2020Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
1112313
CY2020 us-gaap Stock Issued During Period Shares Other
StockIssuedDuringPeriodSharesOther
450761
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
5162000
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
5844000
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.02
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
16000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
28000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
242.70
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y4M6D
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
670000
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
56.83
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
682000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.53
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y11M23D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
456000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
16.74
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y11M1D
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.005
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.004
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
0
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
0
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y5M12D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M14D
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.0114
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.0104
CY2021 ttnp Estimated Forfeiture Rates For Options Granted To Management
EstimatedForfeitureRatesForOptionsGrantedToManagement
0.30
CY2020 ttnp Estimated Forfeiture Rates For Options Granted To Management
EstimatedForfeitureRatesForOptionsGrantedToManagement
0.27
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.29
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.30
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1505000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7000
CY2021 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y1M6D
CY2021Q4 ttnp Operating Loss Carry Forwards Not Subject To Expiration
OperatingLossCarryForwardsNotSubjectToExpiration
49800000
CY2021 ttnp Operating Loss Carryforwards Limitations On Use Percentage
OperatingLossCarryforwardsLimitationsOnUsePercentage
0.80
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
62097000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
64120000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
14738000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
15228000
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1113000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1005000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
77948000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
80353000
CY2021Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
65000
CY2020Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
31000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
65000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
31000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
77883000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
80322000
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
2400000
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
500000
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-1842000
CY2020 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-3830000
CY2021 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-67000
CY2020 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-220000
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-1939000
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-491000
CY2021 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
3000
CY2020 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
26000
CY2021 ttnp Income Tax Reconciliation Revaluation Of Warrant Liability
IncomeTaxReconciliationRevaluationOfWarrantLiability
0
CY2020 ttnp Income Tax Reconciliation Revaluation Of Warrant Liability
IncomeTaxReconciliationRevaluationOfWarrantLiability
194000
CY2021 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
9000
CY2020 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
65000
CY2021 ttnp Tax Attributes Expirations
TaxAttributesExpirations
-3767000
CY2020 ttnp Tax Attributes Expirations
TaxAttributesExpirations
-4352000
CY2021 ttnp Income Tax Reconciliation Impact Of Internal Revenue Code
IncomeTaxReconciliationImpactOfInternalRevenueCode
87000
CY2020 ttnp Income Tax Reconciliation Impact Of Internal Revenue Code
IncomeTaxReconciliationImpactOfInternalRevenueCode
34000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0

Files In Submission

Name View Source Status
0001410578-22-000518-index-headers.html Edgar Link pending
0001410578-22-000518-index.html Edgar Link pending
0001410578-22-000518.txt Edgar Link pending
0001410578-22-000518-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tmb-20211231.xsd Edgar Link pending
tmb-20211231x10k.htm Edgar Link pending
tmb-20211231x10k_htm.xml Edgar Link completed
tmb-20211231xex23d1.htm Edgar Link pending
tmb-20211231xex23d2.htm Edgar Link pending
tmb-20211231xex31d1.htm Edgar Link pending
tmb-20211231xex32d1.htm Edgar Link pending
tmb-20211231_cal.xml Edgar Link unprocessable
tmb-20211231_def.xml Edgar Link unprocessable
tmb-20211231_lab.xml Edgar Link unprocessable
tmb-20211231_pre.xml Edgar Link unprocessable